Arcturus Therapeutics (ARCT) Short Interest Ratio & Short Volume → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free ARCT Stock Alerts $25.98 -0.34 (-1.29%) (As of 05:36 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media Arcturus Therapeutics Short Interest DataCurrent Short Volume4,810,000 sharesPrevious Short Volume4,210,000 sharesChange Vs. Previous Month+14.25%Dollar Volume Sold Short$162.43 millionShort Interest Ratio / Days to Cover10.6Last Record DateMarch 31, 2024Outstanding Shares26,915,000 sharesFloat Size24,540,000 sharesShort Percent of Float19.60%Today's Trading Volume626,328 sharesAverage Trading Volume459,719 sharesToday's Volume Vs. Average136% Short Selling Arcturus Therapeutics ? Sign up to receive the latest short interest report for Arcturus Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatARCT Short Interest Over TimeARCT Days to Cover Over TimeARCT Percentage of Float Shorted Over Time Ad Behind the MarketsTiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>> Arcturus Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/20244,810,000 shares $162.43 million +14.3%19.6%10.6 $33.77 3/15/20244,210,000 shares $152.87 million -0.2%17.2%10 $36.31 2/29/20244,220,000 shares $163.57 million -6.6%17.3%10.1 $38.76 2/15/20244,520,000 shares $172.62 million +3.4%18.6%11.4 $38.19 1/31/20244,370,000 shares $144.08 million +5.3%18.0%10.3 $32.97 1/15/20244,150,000 shares $137.57 million +0.5%17.1%9.8 $33.15 Get the Latest News and Ratings for ARCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/20234,130,000 shares $130.22 million -6.8%17.0%10.1 $31.53 12/15/20234,430,000 shares $127.94 million -18.4%18.2%10.9 $28.88 11/30/20235,430,000 shares $129.99 million +7.1%22.3%13.5 $23.94 11/15/20235,070,000 shares $114.18 million +1.6%20.8%13.1 $22.52 10/31/20234,990,000 shares $95.31 million +4.2%20.6%13.6 $19.10 10/15/20234,790,000 shares $109.79 million +3.9%19.8%12.3 $22.92 9/30/20234,610,000 shares $117.79 million +10.0%19.0%10.8 $25.55 9/15/20234,190,000 shares $119.58 million +6.6%17.3%9.4 $28.54 8/31/20233,930,000 shares $119.28 million +0.3%16.2%8.8 $30.35 8/15/20233,920,000 shares $117.36 million +2.1%16.2%8.9 $29.94 7/31/20233,840,000 shares $134.25 million +5.8%15.9%8.6 $34.96 7/15/20233,630,000 shares $128.65 million +9.0%15.0%8.4 $35.44 6/30/20233,330,000 shares $95.50 million -8.0%13.8%7.7 $28.68 6/15/20233,620,000 shares $99.48 million +0.3%15.0%6.8 $27.48 5/31/20233,610,000 shares $98.70 million +8.7%15.0%7 $27.34 5/15/20233,320,000 shares $101.69 million +5.7%13.8%6.4 $30.63 4/30/20233,140,000 shares $83.59 million +11.7%13.7%6.4 $26.62 4/15/20232,810,000 shares $77.47 million +6.0%12.3%5.9 $27.57 3/31/20232,650,000 shares $63.52 million +4.3%11.6%5.8 $23.97 3/15/20232,540,000 shares $40.49 million +8.6%11.1%7.5 $15.94 2/28/20232,340,000 shares $38.03 million +4.9%10.2%5.8 $16.25 2/15/20232,230,000 shares $41.32 million +21.9%9.8%5.5 $18.53 1/31/20231,830,000 shares $38.67 million +9.6%8.0%3.8 $21.13 1/15/20231,670,000 shares $33.20 million -12.1%7.3%2.9 $19.88 12/30/20221,900,000 shares $32.22 million -27.8%8.3%3.3 $16.96 12/15/20222,630,000 shares $47.97 million -7.4%11.5%4.5 $18.24 11/30/20222,840,000 shares $52.37 million +9.2%12.4%5.2 $18.44 11/15/20222,600,000 shares $46.80 million -10.0%11.4%4.8 $18.00 10/31/20222,890,000 shares $51.15 million +9.5%12.6%5.6 $17.70 10/15/20222,640,000 shares $37.75 million +6.0%11.5%6.2 $14.30 9/30/20222,490,000 shares $36.90 million +9.7%10.9%5.7 $14.82 9/15/20222,270,000 shares $37.18 million +1.3%9.9%4.9 $16.38 8/31/20222,240,000 shares $31.45 million -14.2%9.8%4.1 $14.04 8/15/20222,610,000 shares $56.56 million -7.8%11.4%4.4 $21.67Tiny Biotech Stock Wins $75 Billion Patent (Ad)A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>> ARCT Short Interest - Frequently Asked Questions What is Arcturus Therapeutics' current short interest? Short interest is the volume of Arcturus Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 4,810,000 shares of ARCT short. 19.60% of Arcturus Therapeutics' shares are currently sold short. Learn More on Arcturus Therapeutics' current short interest. What is a good short interest ratio for Arcturus Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ARCT shares currently have a short interest ratio of 11.0. Learn More on Arcturus Therapeutics's short interest ratio. Which institutional investors are shorting Arcturus Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Arcturus Therapeutics: Wolverine Trading LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Arcturus Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 19.60% of Arcturus Therapeutics' floating shares are currently sold short. Is Arcturus Therapeutics' short interest increasing or decreasing? Arcturus Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,810,000 shares, an increase of 14.3% from the previous total of 4,210,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Arcturus Therapeutics' float size? Arcturus Therapeutics currently has issued a total of 26,915,000 shares. Some of Arcturus Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Arcturus Therapeutics currently has a public float of 24,540,000 shares. How does Arcturus Therapeutics' short interest compare to its competitors? 19.60% of Arcturus Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Arcturus Therapeutics: Pliant Therapeutics, Inc. (12.38%), Tango Therapeutics, Inc. (19.42%), OPKO Health, Inc. (28.56%), Tyra Biosciences, Inc. (14.91%), Enliven Therapeutics, Inc. (19.82%), 89bio, Inc. (12.35%), ARS Pharmaceuticals, Inc. (13.13%), ALX Oncology Holdings Inc. (11.47%), Aurinia Pharmaceuticals Inc. (9.57%), Disc Medicine, Inc. (7.71%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Arcturus Therapeutics stock? Short selling ARCT is an investing strategy that aims to generate trading profit from Arcturus Therapeutics as its price is falling. ARCT shares are trading down $0.39 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Arcturus Therapeutics? A short squeeze for Arcturus Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ARCT, which in turn drives the price of the stock up even further. How often is Arcturus Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ARCT, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: Pliant Therapeutics Short Interest Tango Therapeutics Short Interest OPKO Health Short Interest Tyra Biosciences Short Interest Enliven Therapeutics Short Interest 89bio Short Interest ARS Pharmaceuticals Short Interest ALX Oncology Short Interest Aurinia Pharmaceuticals Short Interest Disc Medicine Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ARCT) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsBiden’s $374B Giveaway Into This SectorDTIHe Is Giving Away BitcoinCrypto Swap ProfitsSHOCKING Crypto Leak…Crypto 101 MediaThe #1 Crypto for 2024InvestorPlaceHow Biden has already won 2024Porter & CompanyUrgent alert: open this for a huge profit potentialTimothy Sykes